The first anti-CAIX CAR-T cells clinically tested for the treatment of metastatic ccRCC were CD4TM-γ expressing the first-generation CAR based on murine monoclonal antibody (mAb) G250 applied in high sequential doses in combination with IL-2. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.